US-based OncoMed Pharmaceuticals has started dosing patients in the Phase Ia clinical trial of anti-TIGIT (OMP-313M32) to treat advanced or metastatic solid tumours.

OMP-313M32 is an immuno-oncology therapeutic candidate being developed to prevent immune system suppression, as well as induce anti-tumour activity.

The open-label Phase Ia trial will evaluate the safety and tolerability of increasing doses of anti-TIGIT administered as a monotherapy every two weeks in up to 30 patients at five clinical sites.

OncoMed clinical research and development senior vice-president Robert Stagg said: “In multiple preclinical studies of anti-TIGIT antibodies, we have observed immune activation and single-agent, as well as combination anti-tumour activity, including indications that an anti-TIGIT antibody induced a long-term immune memory response.

“The initiation of this Phase Ia anti-TIGIT study represents the first of our novel immuno-oncology therapeutics to enter clinical trials.

"The initiation of this Phase Ia anti-TIGIT study represents the first of our novel immuno-oncology therapeutics to enter clinical trials."

"We believe that by blocking TIGIT signalling, our anti-TIGIT antibody may enable T-cell activation and facilitate anti-tumour immune responses with the potential to impact tumour growth.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The trial's secondary objectives include anti-TIGIT's pharmacokinetics, immunogenicity and anti-tumour efficacy.

The pharmacodynamic and potential predictive biomarkers for changes in immune system activation will also be assessed.

Anti-TIGIT trial lead investigator Johanna Bendell said: “The immuno-suppressive receptor TIGIT is expressed in many different tumour types, giving us reason to believe that an anti-TIGIT antibody such as OncoMed’s OMP-313M32 has the potential for broad activity in cancer patients."

An expansion cohort will recruit patients with select tumour types, following the determination of a maximum-tolerated dose.